Recent advances in aromatase inhibitor therapy for breast cancer.


Third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane) have emerged as an alternative first-line endocrine treatment for postmenopausal breast cancer patients with hormone-responsive disease. Their clinical efficacy, excellent tolerability, and safety profile compare favorably with that of tamoxifen, which has been the cornerstone of… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.